JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB96028

Anti-ST3GAL2 antibody

4

(2 Reviews)

|

(4 Publications)

Rabbit Polyclonal ST3GAL2 antibody. Suitable for WB and reacts with Human samples. Cited in 4 publications. Immunogen corresponding to Recombinant Fragment Protein within Human ST3GAL2 aa 50-300.

View Alternative Names

SIAT4B, ST3GAL2, Gal-NAc6S, Monosialoganglioside sialyltransferase, ST3Gal II, ST3GalA.2, Sialyltransferase 4B, ST3GalII, SIAT4-B

1 Images
Western blot - Anti-ST3GAL2 antibody (AB96028)
  • WB

Unknown

Western blot - Anti-ST3GAL2 antibody (AB96028)

10% SDS-PAGE

All lanes:

Western blot - Anti-ST3GAL2 antibody (ab96028) at 1/1000 dilution

All lanes:

H1299 whole cell lysate at 30 µg

Predicted band size: 40 kDa

false

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

WB

applications

Immunogen

Recombinant Fragment Protein within Human ST3GAL2 aa 50-300. The exact immunogen used to generate this antibody is proprietary information.

Q16842

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500 - 1/3000", "WB-species-notes": "<p></p>" }, "Mouse": { "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" }, "Rat": { "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" }, "Cow": { "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Immunogen
Storage buffer
pH: 7 Preservative: 0.01% Thimerosal (merthiolate) Constituents: 10% Glycerol (glycerin, glycerine), 1.21% Tris, 0.75% Glycine
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

ST3GAL2 also known as ST3 beta-galactoside alpha-23-sialyltransferase 2 is an enzyme encoded by the ST3GAL2 gene. It is involved in the transfer of sialic acid onto galactose-containing oligosaccharides. The protein has a molecular mass of approximately 38 kDa. ST3GAL2 is expressed in a variety of tissues with higher expression reported in the brain and placenta. It localizes mainly to the Golgi apparatus where it participates in the modification of glycoproteins and glycolipids.
Biological function summary

The enzyme ST3GAL2 contributes to the biosynthesis of sialylated glycoconjugates which are important in cellular communication and stability. It plays a role in producing sialyl Lewis X (sLeX) a ligand involved in cell adhesion. ST3GAL2 operates as part of the Golgi glycosylation machinery and influences the functional properties of cell surface molecules. Its activity impacts processes such as immune response and signaling pathways where the proper display of sialylated structures is required for interacting with selectins.

Pathways

ST3GAL2 plays a vital role in the glycosylation and glycan biosynthesis pathways. It impacts the O-glycan biosynthesis pathway where it contributes to the capping of glycan chains with sialic acid. This sialylation process affects the recognition and binding activities of selectins a family of cell adhesion proteins. In particular ST3GAL2 interacts with other enzymes like ST3GAL1 and ST6GAL1 both of which participate in creating complex glycan structures.

ST3GAL2 associates with cancer and neurological disorders. Altered sialylation patterns driven by overexpression or underexpression of ST3GAL2 can influence tumor progression and metastasis. In cancer changes in glycan structures affect interactions with the immune system and modulate cell migration. Additionally ST3GAL2 connects to disorders involving the immune system as modifications in glycan structures can impact the function of immune-related proteins like selectins influencing inflammatory response and immune escape mechanisms in tumor environments.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

A beta-galactoside alpha2-3 sialyltransferase primarily involved in terminal sialylation of ganglio and globo series glycolipids (PubMed : 8920913, PubMed : 9266697). Catalyzes the transfer of sialic acid (N-acetyl-neuraminic acid; Neu5Ac) from the nucleotide sugar donor CMP-Neu5Ac onto acceptor Galbeta-(1->3)-GalNAc-terminated glycoconjugates through an alpha2-3 linkage (PubMed : 25916169, PubMed : 8920913, PubMed : 9266697). Sialylates GM1/GM1a, GA1/asialo-GM1 and GD1b gangliosides to form GD1a, GM1b and GT1b, respectively (PubMed : 8920913, PubMed : 9266697). Together with ST3GAL3, primarily responsible for biosynthesis of brain GD1a and GT1b that function as ligands for myelin-associated glycoprotein MAG on axons, regulating MAG expression and axonal myelin stability and regeneration (By similarity). Via GT1b regulates TLR2 signaling in spinal cord microglia in response to nerve injury (By similarity). Responsible for the sialylation of the pluripotent stem cell- and cancer stem cell-associated antigen SSEA3, forming SSEA4 (PubMed : 12716912). Sialylates with low efficiency asialofetuin, presumably onto O-glycosidically linked Galbeta-(1->3)-GalNAc-O-Ser (PubMed : 25916169, PubMed : 9266697).
See full target information ST3GAL2

Publications (4)

Recent publications for all applications. Explore the full list and refine your search

Science advances 11:eadg3481 PubMed40614178

2025

Integrated in vivo functional screens and multiomics analyses identify α-2,3-sialylation as essential for melanoma maintenance.

Applications

Unspecified application

Species

Unspecified reactive species

Praveen Agrawal,Shuhui Chen,Ana de Pablos,Yellamandayya Vadlamudi,Fatemeh Vand-Rajabpour,Faezeh Jame-Chenarboo,Swarnali Kar,Amanda Flores Yanke,Pietro Berico,Eleazar Miera Saenz de Vega,Farbod Darvishian,Iman Osman,Amaia Lujambio,Lara K Mahal,Eva Hernando

Science advances 11:eadr0277 PubMed39792681

2025

Screening the human miRNA interactome reveals coordinated up-regulation in melanoma, adding bidirectional regulation to miRNA networks.

Applications

Unspecified application

Species

Unspecified reactive species

Faezeh Jame-Chenarboo,Joseph N Reyes,Nicholas M Twells,Hoi Hei Ng,Dawn Macdonald,Eva Hernando,Lara K Mahal

Laboratory investigation; a journal of technical m 96:731-40 PubMed27088512

2016

Alpha-2, 3-sialyltransferases regulate the multidrug resistance of chronic myeloid leukemia through miR-4701-5p targeting ST3GAL1.

Applications

Unspecified application

Species

Unspecified reactive species

Yan Li,Shihua Luo,Weijie Dong,Xiaobo Song,Huimin Zhou,Lifen Zhao,Li Jia

The Journal of biological chemistry 287:39564-77 PubMed23027862

2012

Golgi phosphoprotein 3 determines cell binding properties under dynamic flow by controlling Golgi localization of core 2 N-acetylglucosaminyltransferase 1.

Applications

ICC/IF

Species

Unspecified reactive species

Mohamed F Ali,Vishwanath B Chachadi,Armen Petrosyan,Pi-Wan Cheng
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com